A new study [140] demonstrated that AZD2811, an AURKB inhibitor, can be formulated in a nanoparticle named accurin to attenuate the side effect and increase the efficacy of AZD2811 in mouse tumor xenograft models, which may give a new direction for the development of AKIs. This evidence concerns the gene AURKB and neoplasm.